These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 26224199

  • 1. Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
    Kooistra HA, Gebel M, Sahin K, Lensing AW, Meijer K.
    Thromb Haemost; 2015 Nov 25; 114(6):1136-43. PubMed ID: 26224199
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral rivaroxaban for symptomatic venous thromboembolism.
    EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.
    N Engl J Med; 2010 Dec 23; 363(26):2499-510. PubMed ID: 21128814
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
    Kahn SR, Springmann V, Schulman S, Martineau J, Stewart JA, Komari N, McLeod A, Strulovitch C, Blostein M, Faucher JP, Gamble G, Gordon W, Kagoma PK, Miron MJ, Laverdière D, Game M, Mills A.
    Thromb Haemost; 2012 Sep 23; 108(3):493-8. PubMed ID: 22782073
    [Abstract] [Full Text] [Related]

  • 8. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
    Bryk AH, Wypasek E, Plens K, Awsiuk M, Undas A.
    Vascul Pharmacol; 2018 Jul 23; 106():22-27. PubMed ID: 29432897
    [Abstract] [Full Text] [Related]

  • 9. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
    Prandoni P, Prins MH, Cohen AT, Müller K, Pap ÁF, Tewes MC, Lensing AW.
    Acad Emerg Med; 2015 Feb 23; 22(2):142-9. PubMed ID: 25676529
    [Abstract] [Full Text] [Related]

  • 10. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L, Mondoly P, Duparc A, Bura-Rivière A, Maury P, Calmels V, Sallerin B, Pathak A, Montastruc JL, Bagheri H.
    Therapie; 2015 Feb 23; 70(6):485-92. PubMed ID: 26223162
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
    Enyart JJ, Jones RJ.
    Ann Pharmacother; 2005 Jun 23; 39(6):1002-7. PubMed ID: 15886295
    [Abstract] [Full Text] [Related]

  • 13. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap ÁF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P.
    Lancet Haematol; 2014 Oct 23; 1(1):e37-46. PubMed ID: 27030066
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
    Woodruff S, Feugère G, Abreu P, Heissler J, Ruiz MT, Jen F.
    J Thromb Thrombolysis; 2016 Nov 23; 42(4):494-504. PubMed ID: 27344439
    [Abstract] [Full Text] [Related]

  • 17. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH.
    J Med Econ; 2014 Oct 23; 17(10):691-5. PubMed ID: 25065536
    [Abstract] [Full Text] [Related]

  • 18. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Di Nisio M, Vedovati MC, Riera-Mestre A, Prins MH, Mueller K, Cohen AT, Wells PS, Beyer-Westendorf J, Prandoni P, Bounameaux H, Kubitza D, Schneider J, Pisters R, Fedacko J, Fontes-Carvalho R, Lensing AW.
    Thromb Haemost; 2016 Sep 27; 116(4):739-46. PubMed ID: 27535349
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.